PARSIPPANY, NJ, Jan. 20, 2021 (Globe NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) introduced right now that it will maintain its 3rd quarter 2020 economical effects convention call and webcast just after the close of industry on Thursday, January 21, 2021 at 4:30 p.m. ET.
Purpose: To update the market place on Interpace’s third quarter 2020 money effects
Day and Time: Thursday, January 21, 2021 at 4:30 p.m. ET
Dial-in Number (Domestic): +1 (877) 407 – 9716
Dial-in Selection (International): +1 (201) 493 – 6779
Convention ID: 13714992
Webcast Access: http://general public.viavid.com/index.php?id=143006
All listeners should really affirm they are dialing in for the Interpace Biosciences convention connect with with the operator who will immediately location them into the phone. A webcast replay will be readily available on the Company’s site ( www.interpace.com ) about two several hours following completion of the phone and will be archived on the Company’s web page for 90 times.
About Interpace Biosciences
Interpace Biosciences is an emerging chief in enabling personalized drugs, providing specialized expert services alongside the therapeutic worth chain from early analysis and prognostic arranging to specific therapeutic apps.
Scientific solutions, by Interpace Diagnostics, provides clinically helpful molecular diagnostic assessments, bioinformatics and pathology providers for assessing chance of most cancers by leveraging the most current know-how in individualized medicine for improved patient prognosis and management. Interpace has 4 commercialized molecular exams and one examination in a medical analysis approach (CEP): PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts ThyGeNEXT® for the analysis of thyroid cancer from thyroid nodules making use of a following technology sequencing assay ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules employing a proprietary gene expression assay and RespriDX® that differentiates lung most cancers of main vs. metastatic origin. In addition, BarreGEN® for Barrett’s Esophagus, is now in a clinical analysis software whereby we get data from physicians working with BarreGEN® to guide us in positioning the item for comprehensive launch, partnering and likely supporting reimbursement with payers.
Pharma companies, as a result of Interpace Pharma Remedies, supplies pharmacogenomics screening, genotyping, biorepository and other tailored products and services to the pharmaceutical and biotech industries. Pharma products and services also progress personalised drugs by partnering with pharmaceutical, educational, and technological innovation leaders to successfully integrate pharmacogenomics into their drug growth and medical trial packages with the targets of offering safer, much more helpful medications to sector more promptly, and strengthening individual care.
For more data, you should go to Interpace Biosciences’ site at www.interpace.com.
This push launch has forward-hunting statements inside of the which means of Section 27A of the Securities Act of 1933, Portion 21E of the Securities Trade Act of 1934 and the Personal Securities Litigation Reform Act of 1995, relating to the Company’s long term financial and functioning performance. The Enterprise has attempted to identify ahead seeking statements by terminology which includes “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other text that express uncertainty of potential events or results to identify these forward-searching statements. These statements are dependent on recent anticipations, assumptions and uncertainties involving judgments about, amongst other things, long run financial, aggressive and industry circumstances and potential company choices, all of which are hard or difficult to predict precisely and a lot of of which are beyond the Company’s manage. These statements also involve known and not known pitfalls, uncertainties and other components that may trigger the Company’s actual benefits to be materially unique from those people expressed or implied by any forward-hunting statements. Moreover, all ahead-wanting statements are subject to the “Risk Factors” detailed from time to time in the Company’s most current Once-a-year Report on Form 10-K submitted on April 22, 2020, Recent Stories on Form 8-K and Quarterly Stories on Variety 10-Q. Simply because of these and other threats, uncertainties and assumptions, undue reliance should really not be placed on these ahead-seeking statements. In addition, these statements converse only as of the date of this push release and, other than as could be required by regulation, the Business undertakes no obligation to revise or update publicly any forward-seeking statements for any rationale.
Joseph Green/ Megan Paul
[email protected]/[email protected]